View Older Stories
-
Form SCHEDULE 13G SkyWater Technology, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Rallybio Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Sagimet Biosciences Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Research Alliance Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Nasus Pharma Ltd Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Quince Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Neurogene Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G JATT II Acquisition Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Korro Bio, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Contineum Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Cyclerion Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Helix Acquisition Corp. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Cellectar Biosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Camp4 Therapeutics Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Camp4 Therapeutics closes second tranche of $100M private placement
-
Obsidian Therapeutics completes Galera merger, raises $350M
-
Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial
-
Jasper Therapeutics completes Kira acquisition, raises $132M
-
NextCure and Avere to merge, targeting oral IL-23 therapy
-
Boundless Bio agrees to merge with Serapha Bio in all-stock deal
-
Research Alliance Corporation III prices $75 million IPO at $10 per share
-
Quince acquires Orphai for LAM-001 drug, raises up to $187 million
-
Form SCHEDULE 13G Contineum Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Enhabit, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Helix Acquisition Corp. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Camp4 Therapeutics Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Talkspace, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Rallybio Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Nasus Pharma Ltd Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G TXNM ENERGY INC Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Korro Bio Ops, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Cellectar Biosciences raises up to $140 million in oversubscribed financing
-
Sagimet prices $175 million stock offering at $6 per share
-
Adlai Nortye raises $150 million in private placement financing

